Background 

This study aimed to identify whether NTR is the independent risk factor for progression-free survival (PFS) and overall survival (OS) in patients treated with concurrent chemo-radiotherapy (cCRT).

Methods 

We retrospectively studied 106 T1-4N1-3M0 non-small cell lung cancer patients treated with cCRT. The maximum standardized uptake value (SUVTumor) of the primary tumor and the metastatic lymph nodes (SUVLN) were measured. The prognostic significance of NTR for predicting PFS and OS was assessed. A multi-adjusted spline regression model was conducted to provide more precise estimates and examine the shape of the associations between NTR and the risk of progression.

Results 

From 2012 to 2017, 106 eligible patients were analyzed. The median follow-up time was 15.3 months (3.5–44.6 months). We determined the maximizing area under the time-dependent receiver operating characteristic curve was at an NTR of 0.73 for predicting PFS. The two-year PFS was significantly lower in the high-NTR group (35.7% vs. 55.4%, P = 0.02) and two-year OS (43.4% vs. 61.1%, P = 0.03 was also significantly worse. Multivariable analysis revealed that only NTR was an independent prognostic factor for PFS (hazard ratio [HR]: 10.04, P < 0.001) and OS (HR: 4.19, P = 0.03). The restricted cubic spline regression model showed that NTR had a non-linear relationship with log relative risk for progression.

Conclusion 

NTR was an independent risk factor for predicting PFS and OS in T1-4N1-3M0 non-small cell lung cancer patients treated with cCRT.

中文翻译：

---

淋巴结与原发肿瘤最大标准化摄取值比对同步放化疗T1-4N1-3M0非小细胞肺癌患者的预后价值

背景 

本研究旨在确定 NTR 是否是同步放化疗 (cCRT) 患者无进展生存期 (PFS) 和总生存期 (OS) 的独立危险因素。

方法 

我们回顾性研究了 106 名接受 cCRT 治疗的 T1-4N1-3M0 非小细胞肺癌患者。测量原发肿瘤和转移淋巴结(SUVLN)的最大标准化摄取值(SUVTumor)。评估了 NTR 对预测 PFS 和 OS 的预后意义。进行多重调整样条回归模型以提供更精确的估计并检查 NTR 与进展风险之间的关联形状。

结果 

从2012年到2017年，对106名符合条件的患者进行了分析。中位随访时间为 15.3 个月（3.5-44.6 个月）。我们确定时间依赖性受试者工作特征曲线下的最大面积 NTR 为 0.73，用于预测 PFS。高 NTR 组的两年 PFS 显着较低（35.7% vs. 55.4%，P = 0.02），两年 OS（43.4% vs. 61.1%，P = 0.03）也显着较差。多变量分析显示表明只有NTR是PFS（风险比[HR]：10.04， P < 0.001）和OS（HR：4.19，P = 0.03）的独立预后因素。限制三次样条回归模型显示NTR具有非线性关系具有对数相对进展风险。

结论 

NTR 是预测接受 cCRT 治疗的 T1-4N1-3M0 非小细胞肺癌患者 PFS 和 OS 的独立危险因素。